BARBEZAN, ANGELICA B.ROSERO, WILMMER A.A.VIEIRA, DANIEL P.RIGO, MARIA E.Z.SILVA, GIOVANA D. daRODRIGUES, ALEX A.ALMEIDA, LUIS F. deSILVA, FABIO F.A. daRIVERA, ANDY G.SILVA, NATANAEL G. daBERNARDES, EMERSON S.ROSTELATO, MARIA E.C.M.2026-03-132026-03-132025BARBEZAN, ANGELICA B.; ROSERO, WILMMER A.A.; VIEIRA, DANIEL P.; RIGO, MARIA E.Z.; SILVA, GIOVANA D. da; RODRIGUES, ALEX A.; ALMEIDA, LUIS F. de; SILVA, FABIO F.A. da; RIVERA, ANDY G.; SILVA, NATANAEL G. da; BERNARDES, EMERSON S.; ROSTELATO, MARIA E.C.M. Evaluation of198Au nanoparticles coated with gum arabic for prostate cancer: a contextual comparison with BSA-coated. <b>ACS Omega</b>, v. 10, n. 28, p. 30207-30221, 2025. DOI: <a href="https://dx.doi.org/10.1021/acsomega.5c01385">10.1021/acsomega.5c01385</a>. Disponível em: https://repositorio.ipen.br/handle/123456789/49433.2470-1343https://repositorio.ipen.br/handle/123456789/49433Prostate cancer, a leading cause of morbidity and mortality among men, requires safer and more effective therapeutic approaches. Nanotechnology has emerged as a promising strategy to optimize therapeutic agent distribution and reduce adverse effects of conventional treatments. This study presents the development and evaluation of radioactive gold nanoparticles (198AuNPs) coated with gum arabic (GA) for prostate cancer treatment. While BSA-coated nanoparticles have been previously studied by our group, demonstrating therapeutic effectiveness, stability, and biocompatibility, the current work focuses exclusively on the GA formulation, which features a distinct synthesis protocol. In vitro and in vivo assays with198AuNPs-GA demonstrated good stability, low toxicity in nontumor cells, tumor retention, and reduced tumor growth in animal models. References to BSA are included only for contextual comparison. These findings support the feasibility of gum arabic-coated198AuNPs and offer new insights for enhancing future clinical strategies.30207-30221engopenAccessArtigo de periódico281010.1021/acsomega.5c01385https://orcid.org/0000-0002-0007-534Xhttps://orcid.org/0000-0002-0029-7313https://orcid.org/0000-0003-2943-609766.376.50